FAB vs. IMM, ORPH, HVO, REDX, ETX, HEMO, SBTX, SAR, POLB, and COS
Should you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include ImmuPharma (IMM), Open Orphan (ORPH), hVIVO (HVO), Redx Pharma (REDX), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), SkinBioTherapeutics (SBTX), Sareum (SAR), Poolbeg Pharma (POLB), and Collagen Solutions plc (COS.L) (COS). These companies are all part of the "biotechnology" industry.
Fusion Antibodies vs. Its Competitors
Fusion Antibodies (LON:FAB) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
12.5% of Fusion Antibodies shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 6.8% of Fusion Antibodies shares are held by company insiders. Comparatively, 8.1% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ImmuPharma has a net margin of 3,519.56% compared to Fusion Antibodies' net margin of -195.95%. ImmuPharma's return on equity of -131.41% beat Fusion Antibodies' return on equity.
Fusion Antibodies has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
ImmuPharma has lower revenue, but higher earnings than Fusion Antibodies. ImmuPharma is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.
In the previous week, ImmuPharma had 28 more articles in the media than Fusion Antibodies. MarketBeat recorded 28 mentions for ImmuPharma and 0 mentions for Fusion Antibodies. ImmuPharma's average media sentiment score of 0.29 beat Fusion Antibodies' score of 0.00 indicating that ImmuPharma is being referred to more favorably in the news media.
Summary
ImmuPharma beats Fusion Antibodies on 9 of the 12 factors compared between the two stocks.
Get Fusion Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Antibodies Competitors List
Related Companies and Tools
This page (LON:FAB) was last updated on 9/13/2025 by MarketBeat.com Staff
Free FAB Stock Alerts